Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Jung-gu, Korea, Republic of Clinical Trials

A listing of Jung-gu, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (861) clinical trials

Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in na ve Chronic Hepatitis B

This is an open-label, single arm cohort study to see efficacy and safety of tenofovir disoproxil fumarate (TDF) in nave chronic hepatitis B, retrospectively and prospectively both.

Phase N/A

0.0 miles

Learn More »

A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs

Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean patients with Hepatitis C.

Phase N/A

0.0 miles

Learn More »

Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)

Efficacy of aflibercept for diabetic macular edema was demonstrated in the phase III, VIVID and VISTA studies. In these studies, aflibercept was injected using the fixed dosing regimen that an intravitreal injection was performed 5 times every 4 weeks and then every 8 weeks. Although the efficacy was comparable to ...

Phase

0.0 miles

Learn More »

DP-R212 Pharmacokinetic Study

An open-label, multiple-dose study to evaluate the pharmacokinetic drug-drug interaction of amlodipine and rosuvastatin in healthy adult male subjects.

Phase

0.0 miles

Learn More »

A Study With Upatacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

This is a Phase 3 multicenter study that includes two periods. Period 1 is a 12-week, randomized, double-blind, parallel-group, placebo-controlled period designed to compare the safety and efficacy of upadacitinib versus placebo for the treatment of signs and symptoms of participants with moderately to severely active RA who are on ...

Phase

0.0 miles

Learn More »

A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)

Primary Outcome Measure: Complete histopathological regression from baseline [Time Frame: Baseline through Week 16] Secondary Outcome Measures: Change from baseline of CIN classification [Time Frame: Baseline through Week 16] Change from baseline of RCI [Time Frame: Baseline through Week 16 and Week 32] Change from baseline of cytopathological classification based ...

Phase

0.25 miles

Learn More »

Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort Turbuhaler in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

The purpose of this study is to demonstrate the superiority of CHF 5993 pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) over Symbicort Turbuhaler in terms of pulmonary function, as well as to assess its safety.

Phase

0.43 miles

Learn More »

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The trial is an open label extension study. Eligible patients from the RPC01-3101 and RPC01-202 trials will have the option to enroll in this trial to receive study medication for up to 5 years or until marketed approval

Phase

1.03 miles

Learn More »

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA

As T790M is the most common mechanism of acquired resistance to EGFR TKI, EGFR TKIs targeting T790M has been developed. AZD9291 is an oral, potent, irreversible EGFR-TKI selective for sensitizing (EGFRm) and T790M resistance mutation with a significant selectivity margin against wild-type EGFR. As a result, AZD9291 can effectively block ...

Phase

1.03 miles

Learn More »

Observational Study of Pertuzumab Safety in Participants With Breast Cancer

This Phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) will evaluate the safety of pertuzumab in approximately 3000 participants with metastatic or locally unresectable recurrent breast cancer who have never received chemotherapy or anti-human epidermal growth factor receptor 2 (HER2) therapy for their metastatic disease with HER2 positivity in ...

Phase N/A

1.05 miles

Learn More »